[
  {
    "ts": null,
    "headline": "BD Launches Urine Complete Cup Kit for Smarter Testing & Accuracy",
    "summary": "BDX launches a three-tube urine collection kit to expand testing from one sample, aiming to boost lab efficiency and reduce contamination risks.",
    "url": "https://finnhub.io/api/news?id=95e40bf1cea3393ad695bb7eba68c437198f430dd907a6710f768974445a6da2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771954800,
      "headline": "BD Launches Urine Complete Cup Kit for Smarter Testing & Accuracy",
      "id": 139201025,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CAH",
      "source": "Yahoo",
      "summary": "BDX launches a three-tube urine collection kit to expand testing from one sample, aiming to boost lab efficiency and reduce contamination risks.",
      "url": "https://finnhub.io/api/news?id=95e40bf1cea3393ad695bb7eba68c437198f430dd907a6710f768974445a6da2"
    }
  },
  {
    "ts": null,
    "headline": "Hims & Hers Stock Slips Despite Q4 Earnings Beat, Margins Contract",
    "summary": "HIMS reports an earnings beat and strong revenue growth in fourth-quarter 2025, but margin pressure and a softer outlook clouded the quarterly performance.",
    "url": "https://finnhub.io/api/news?id=81e86bc82656331208d22985b62e8fa32f2a3bc1f33496d36e71e1092e65824b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771953300,
      "headline": "Hims & Hers Stock Slips Despite Q4 Earnings Beat, Margins Contract",
      "id": 139200995,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CAH",
      "source": "Yahoo",
      "summary": "HIMS reports an earnings beat and strong revenue growth in fourth-quarter 2025, but margin pressure and a softer outlook clouded the quarterly performance.",
      "url": "https://finnhub.io/api/news?id=81e86bc82656331208d22985b62e8fa32f2a3bc1f33496d36e71e1092e65824b"
    }
  },
  {
    "ts": null,
    "headline": "HSIC Q4 Earnings & Revenues Beat Estimates, Margins Down",
    "summary": "Henry Schein tops Q4 estimates with 7.8% sales growth, but margin contraction tempers strong equipment, specialty and tech gains.",
    "url": "https://finnhub.io/api/news?id=b248d604ccbc86e3d0e6a8f4f57478d0109cd7256a148f8cdd8b3d9c43b3f2df",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771940760,
      "headline": "HSIC Q4 Earnings & Revenues Beat Estimates, Margins Down",
      "id": 139197510,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CAH",
      "source": "Yahoo",
      "summary": "Henry Schein tops Q4 estimates with 7.8% sales growth, but margin contraction tempers strong equipment, specialty and tech gains.",
      "url": "https://finnhub.io/api/news?id=b248d604ccbc86e3d0e6a8f4f57478d0109cd7256a148f8cdd8b3d9c43b3f2df"
    }
  },
  {
    "ts": null,
    "headline": "MYGN Stock Up on Q4 Earnings and Revenue Beat, Gross Margin Down",
    "summary": "Myriad Genetics jumps 21% after Q4 earnings beat estimates by 350% and revenues top forecasts, even as gross margin slips and mental health sales decline.",
    "url": "https://finnhub.io/api/news?id=d8f5516e0d7e6d5aa26d90fd3470f7166fe1e82a203ea106d1ef504075126c65",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771937100,
      "headline": "MYGN Stock Up on Q4 Earnings and Revenue Beat, Gross Margin Down",
      "id": 139197511,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CAH",
      "source": "Yahoo",
      "summary": "Myriad Genetics jumps 21% after Q4 earnings beat estimates by 350% and revenues top forecasts, even as gross margin slips and mental health sales decline.",
      "url": "https://finnhub.io/api/news?id=d8f5516e0d7e6d5aa26d90fd3470f7166fe1e82a203ea106d1ef504075126c65"
    }
  },
  {
    "ts": null,
    "headline": "Cardinal Health report highlights cost savings and provider confidence in biosimilars",
    "summary": "Cardinal Health (NYSE: CAH) today released its 2026 Biosimilars Report: Driving access and patient outcomes in physician practices, which highlights the substantial savings biosimilars have delivered to the U.S. healthcare system and the strong confidence providers have in these treatments.",
    "url": "https://finnhub.io/api/news?id=07a76db29d571800faaf296545539da25d90b381adcb22e36cd8e907c8e3d5a8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771934400,
      "headline": "Cardinal Health report highlights cost savings and provider confidence in biosimilars",
      "id": 139194677,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CAH",
      "source": "Yahoo",
      "summary": "Cardinal Health (NYSE: CAH) today released its 2026 Biosimilars Report: Driving access and patient outcomes in physician practices, which highlights the substantial savings biosimilars have delivered to the U.S. healthcare system and the strong confidence providers have in these treatments.",
      "url": "https://finnhub.io/api/news?id=07a76db29d571800faaf296545539da25d90b381adcb22e36cd8e907c8e3d5a8"
    }
  },
  {
    "ts": null,
    "headline": "Barclays Maintains Overweight on Cardinal Health, Raises Price Target to $258",
    "summary": "Barclays  analyst Glen Santangelo   maintains Cardinal Health (NYSE:CAH) with a Overweight and raises the price target from $243 to $258.",
    "url": "https://finnhub.io/api/news?id=b02abd0bcc1c644070bd92e18a6bfa940f8aa57c8b47cd3a1b9927ce53e846af",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771928550,
      "headline": "Barclays Maintains Overweight on Cardinal Health, Raises Price Target to $258",
      "id": 139208700,
      "image": "",
      "related": "CAH",
      "source": "Benzinga",
      "summary": "Barclays  analyst Glen Santangelo   maintains Cardinal Health (NYSE:CAH) with a Overweight and raises the price target from $243 to $258.",
      "url": "https://finnhub.io/api/news?id=b02abd0bcc1c644070bd92e18a6bfa940f8aa57c8b47cd3a1b9927ce53e846af"
    }
  }
]